Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
Condition: Non-Small Cell Lung Cancer Metastatic Interventions: Drug: Durvalumab; Drug: Pemetrexed; Drug: Carboplatin Sponsors: University of Utah; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | AstraZeneca | Cancer & Oncology | Immunotherapy | Non-Small Cell Lung Cancer | Research